Page last updated: 2024-09-04

atrasentan and bay 94-8862

atrasentan has been researched along with bay 94-8862 in 2 studies

Compound Research Comparison

Studies
(atrasentan)
Trials
(atrasentan)
Recent Studies (post-2010)
(atrasentan)
Studies
(bay 94-8862)
Trials
(bay 94-8862)
Recent Studies (post-2010) (bay 94-8862)
3584110818337179

Protein Interaction Comparison

ProteinTaxonomyatrasentan (IC50)bay 94-8862 (IC50)
Mineralocorticoid receptor Homo sapiens (human)0.0275

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Batu Demir, D; Cooper, ME1
Heerspink, HJL; Muskiet, MHA; Wheeler, DC1

Reviews

2 review(s) available for atrasentan and bay 94-8862

ArticleYear
New strategies to tackle diabetic kidney disease.
    Current opinion in nephrology and hypertension, 2016, Volume: 25, Issue:4

    Topics: Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Atrasentan; Diabetes Mellitus; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Endothelin Receptor Antagonists; Humans; Hypoglycemic Agents; Kidney Failure, Chronic; Mineralocorticoid Receptor Antagonists; Naphthyridines; Pyrrolidines; Renal Artery; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Sympathectomy

2016
New pharmacological strategies for protecting kidney function in type 2 diabetes.
    The lancet. Diabetes & endocrinology, 2019, Volume: 7, Issue:5

    Topics: Antihypertensive Agents; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelin Receptor Antagonists; Humans; Hypoglycemic Agents; Incretins; Mineralocorticoid Receptor Antagonists; Naphthyridines; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors

2019